Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arena Pharmaceutical (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 764,069
  • Shares Outstanding, K 31,770
  • Annual Sales, $ 123,980 K
  • Annual Income, $ -22,520 K
  • 36-Month Beta 1.30
  • Price/Sales 6.04
  • Price/Cash Flow 0.00
  • Price/Book 27.23

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.54 +65.41%
on 06/23/17
27.86 -13.68%
on 07/11/17
+7.45 (+44.88%)
since 06/21/17
3-Month
11.30 +112.83%
on 05/18/17
27.86 -13.68%
on 07/11/17
+11.05 (+85.00%)
since 04/21/17
52-Week
11.30 +112.83%
on 05/18/17
27.86 -13.68%
on 07/11/17
+6.25 (+35.11%)
since 07/21/16

Most Recent Stories

More News
Arena Announces Secondary Stock Worth $150M (revised)

Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.

ENZ : 11.35 (-1.05%)
AZN : 34.05 (+0.47%)
ARNA : 24.05 (+1.99%)
EXEL : 27.23 (+0.89%)
Top Ranked Momentum Stocks to Buy for July 14th

Top Ranked Momentum Stocks to Buy for July 14th

CAT : 106.59 (-0.68%)
TITN : 18.13 (+0.39%)
LVS : 62.36 (+0.32%)
ARNA : 24.05 (+1.99%)
Why Arena Pharmaceuticals (ARNA) Could Be Positioned for a Surge

Arena Pharmaceuticals (ARNA) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

ARNA : 24.05 (+1.99%)
Arena Pharmaceuticals prices public offering at USD24.00 per share

Biopharmaceutical company Arena Pharmaceuticals Inc (NASDAQ:ARNA) said on Wednesday that it has priced a public offering of 6,250,000 common stock shares.

ARNA : 24.05 (+1.99%)
Company News for July 12, 2017

Companies in the News are: FOLD,SLP,ARNA,EVGN,MON

FOLD : 13.53 (-0.59%)
SLP : 15.25 (+0.66%)
EVGN : 5.22 (-0.95%)
ARNA : 24.05 (+1.99%)
MON : 117.38 (+0.32%)
Arena Announces Secondary Stock Offering of 150M Shares

Arena Pharmaceuticals, Inc. (ARNA) plans to offer and sell 150 million shares of its common stock, subject to customary closing conditions.

ENZ : 11.35 (-1.05%)
AZN : 34.05 (+0.47%)
ARNA : 24.05 (+1.99%)
EXEL : 27.23 (+0.89%)
Biotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal

Arena (ARNA) saw it shares shoot up on mid-stage data on its pulmonary arterial hypertension drug while quite a few companies provided regulatory updates.

FOLD : 13.53 (-0.59%)
CELG : 137.74 (+1.05%)
VRTX : 163.17 (+2.41%)
ARNA : 24.05 (+1.99%)
GILD : 73.76 (+0.46%)
AMGN : 180.21 (+0.50%)
OCUL : 6.72 (-2.33%)
E*Trade Financial, Statoil, Arena Pharmaceuticals, Johnson & Johnson and United Therapeutics highlighted as Zacks Bull and Bear of the Day

E*Trade Financial, Statoil, Arena Pharmaceuticals, Johnson & Johnson and United Therapeutics highlighted as Zacks Bull and Bear of the Day

JNJ : 135.31 (-0.92%)
ARNA : 24.05 (+1.99%)
ETFC : 41.63 (+5.13%)
UTHR : 129.98 (-1.05%)
STO : 17.26 (-1.32%)
Biotech Stocks Ride Momentum in Anticipation of Favorable Governmental Policy Environment

Biotech and Pharma Companies with innovative technologies and development pipelines are gaining strong interest among investors as treatments and therapies for serious diseases and conditions are in high...

FOLD : 13.53 (-0.59%)
ARNA : 24.05 (+1.99%)
CPRX : 2.95 (-3.28%)
MBRX : 1.91 (+0.53%)
OCUL : 6.72 (-2.33%)
Arena Pharmaceuticals expects USD150.0m from proposed public offering of common stock

Biopharmaceutical company Arena Pharmaceuticals Inc (NASDAQ:ARNA) said on Tuesday that it plans to offer and sell USD150.0m shares of its common stock in an underwritten public offering.

ARNA : 24.05 (+1.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their...

See More

Support & Resistance

2nd Resistance Point 24.81
1st Resistance Point 24.43
Last Price 24.05
1st Support Level 23.52
2nd Support Level 23.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.